0% of Alzheimer’s patients are undetected.
AlziDetect is one of the world’s first early Alzheimer’s risk screening platforms.
Using MediaPipe facial landmark tracking (468 points) and vertical eye-face coupling patterns reported in Alzheimer’s research, we flag early risk signals in under ~10 min and indicate when further clinical evaluation may be appropriate.
Our ecosystem centers around early risk screening through our proprietary gaze screening, supported by clinician-guided education, continuous progress monitoring, and memory preservation tools to coordinate follow-up care.
Tracking vertical eye-face coupling patterns from MediaPipe’s 468-point facial landmarks to flag early risk signals.
Access clinician-led education and support to understand screening results and possible next steps.
Track screening trends over time with AI-powered analytics to support follow-up conversations.
Preserve precious memories with our AI-assisted memory recording and organization system.
Flagging risk patterns years before traditional evaluation, enabling earlier follow-up when support is most effective.
By making screening accessible from home, we're removing barriers that prevent millions from getting timely follow-up.
From weeks of waiting to screening results in minutes, enabling faster follow-up when it matters most.
Proprietary data taken from our clinic and hospital partners.
Architect innovative testing protocols and analysis frameworks optimized for early risk screening.
Launch targeted data collection and validation studies with clinical partners.
Develop and train AI models on comprehensive datasets to achieve strong screening performance.
Rigorously test and validate model performance against clinical standards.
Scale the platform to serve patients and healthcare providers continuously.
Our technology is built on a foundation of rigorous scientific research and validated through partnerships with leading medical institutions and research organizations.
Our screening algorithms are based on peer-reviewed research from leading medical journals and institutions worldwide.
Key Research Area:
MediaPipe facial landmark tracking (468 points) and vertical eye-face coupling patterns reported in Alzheimer’s research
We work closely with hospitals and clinics to validate our technology in real-world clinical settings.
Partnership Focus:
Proprietary data collection and validation studies with clinical partners
Our methodology is backed by peer-reviewed research from leading medical institutions.
Continuous collaboration with research institutions ensures our technology stays at the forefront of early risk screening research.
Ongoing Research:
Focused gaze screening using MediaPipe facial landmarks and vertical eye-face coupling patterns
Our team is dedicated to developing the best possible technology for early Alzheimer’s risk screening and care support.
Founder
Passionate Neurobiologist and Entrepreneur
Ensuring healthcare access is available to everyone
Co-Founder
Entrepreneur & Systems Designer
Making early risk screening accessible.
AI and web engineer
AI and Health Integrated Engineer
Engineering meaningful solutions.
Backend & AI Engineer
Entrepreneur & Full-stack Developer
AI for real-world impact.
AI Engineer
Programmer in Healthcare AI
Technology that improves lives.
This Alzheimer’s risk screening uses your web camera to track facial landmarks for screening. Webcam data is used only for screening, and no raw video is stored without consent. Click YES if you wish to proceed.
Risk Screening Result:
Confidence:
This screening does NOT diagnose Alzheimer’s disease. It flags whether further clinical evaluation may be appropriate.
